Investigation of the synergistic effect of glimepiride and rosuvastatin on alloxan-induced diabetic rat

Mondol, Debashish; Islam, Md. Nahinul; Biswas, Sonchita; Jodder, Protic; Sana, Samiron; Saleh, Md. Abu; Islam, Md. Rafiqul

doi:10.1007/s40200-020-00662-6

Cited by 4 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our experiments, alloxan administration induced, from day 2 after injection, a syndrome resembling human T1DM [ 19 , 20 , 28 ] that was confirmed by measurement of blood glucose levels. Our animals were chronically treated with the antidepressant fluoxetine, which increases extracellular serotonin levels [ 29 ] at a dose and period (10 mg/kg/day; 14 days) that originate levels in plasma similar to patients treated with therapeutic doses [ 25 , 27 , 30 , 31 , 32 ].…”

Section: Discussionsupporting

confidence: 65%

Fluoxetine Treatment Decreases Cardiac Vagal Input and Alters the Serotonergic Modulation of the Parasympathetic Outflow in Diabetic Rats

García-Domingo

García-Pedraza

Fernández-González

et al. 2022

IJMS

View full text Add to dashboard Cite

Comorbid diabetes and depression constitutes a major health problem, worsening associated cardiovascular diseases. Fluoxetine’s (antidepressant) role on cardiac diabetic complications remains unknown. We determined whether fluoxetine modifies cardiac vagal input and its serotonergic modulation in male Wistar diabetic rats. Diabetes was induced by alloxan and maintained for 28 days. Fluoxetine was administered the last 14 days (10 mg/kg/day; p.o). Bradycardia was obtained by vagal stimulation (3, 6 and 9 Hz) or i.v. acetylcholine administrations (1, 5 and 10 μg/kg). Fluoxetine treatment diminished vagally-induced bradycardia. Administration of 5-HT originated a dual action on the bradycardia, augmenting it at low doses and diminishing it at high doses, reproduced by 5-CT (5-HT1/7 agonist). 5-CT did not alter the bradycardia induced by exogenous acetylcholine. Decrease of the vagally-induced bradycardia evoked by high doses of 5-HT and 5-CT was reproduced by L-694,247 (5-HT1D agonist) and blocked by prior administration of LY310762 (5-HT1D antagonist). Enhancement of the electrical-induced bradycardia by 5-CT (10 μg/kg) was abolished by pretreatment with SB269970 (5-HT7 receptor antagonist). Thus, oral fluoxetine treatment originates a decrease in cardiac cholinergic activity and changes 5-HT modulation of bradycardic responses in diabetes: prejunctional 5-HT7 receptors augment cholinergic-evoked bradycardic responses, whereas prejunctional 5-HT1D receptors inhibit vagally-induced bradycardia.

show abstract

Section: Discussionsupporting

confidence: 65%

Fluoxetine Treatment Decreases Cardiac Vagal Input and Alters the Serotonergic Modulation of the Parasympathetic Outflow in Diabetic Rats

García-Domingo

García-Pedraza

Fernández-González

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

Antidiabetic potency of glimepiride and naringin: an in silico and in vitro investigation

Rath,

Pattnaik,

Kar

et al. 2024

Journal of Biomolecular Structure and Dynamics

View full text Add to dashboard Cite

Effectiveness and Safety of Use of Biguanide and Sulfonylurea Drugs With Histopathological Analysis and Parameters of the Kidney, Liver and Pancreas in Alloxan-Induced Rats

WAHYUNI,

RAHMAWATI,

WIJIANTO

et al. 2024

Int J App Pharm

View full text Add to dashboard Cite

Objective: There are several drugs used as first-line in the treatment of type 2 diabetes with different mechanisms of action, such as metformin, glimepiride, and glibenclamide. The mechanism action of the drugs through stimulation and increased insulin sensitivity. This mechanism can have side effects on the organs excreting the drug. The aim of this study was to compare the effectiveness and safety of the three drugs in alloxan-induced rats. Methods: A total of 15 rats were divided into five groups with each group consisting of three rats: Normal Control (NC), Induced Control (DC), Metformin 9 mg/kgBW, Glimepiride 1 mg/kgBW, and Glibenclamide 5 mg/KgBW. Fasting Blood Glucose (FBG) levels, Blood Urea Nitrogen (BUN), Creatinine Serum (SCr) and Serum Glutamate Pyruvate Transaminase (SGPT) were obtained. Data analysis using ANOVA and a post-hoc test. Results: The results show that in comparison of the three anti-diabetic drugs, glibenclamide causes the highest damage to the pancreas and liver. Meanwhile, glimepiride provides the safest results for the kidneys, and metformin is safest for the liver. Conclusion: The result showed that the drug glibenclamide caused the highest damage to pancreatic cells and glimepiride gave the greatest decrease in blood glucose levels, but the use of glimepiride for 14 d was safer for use than for glibenclamide for kidney parameters.

show abstract

Investigation of the synergistic effect of glimepiride and rosuvastatin on alloxan-induced diabetic rat

Cited by 4 publications

References 37 publications

Fluoxetine Treatment Decreases Cardiac Vagal Input and Alters the Serotonergic Modulation of the Parasympathetic Outflow in Diabetic Rats

Fluoxetine Treatment Decreases Cardiac Vagal Input and Alters the Serotonergic Modulation of the Parasympathetic Outflow in Diabetic Rats

Antidiabetic potency of glimepiride and naringin: an in silico and in vitro investigation

Effectiveness and Safety of Use of Biguanide and Sulfonylurea Drugs With Histopathological Analysis and Parameters of the Kidney, Liver and Pancreas in Alloxan-Induced Rats

Contact Info

Product

Resources

About